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Abstract
Background: Immunotherapy targeting the checkpoint PD1 (programmed cell death protein 1) or PDL1
(programmed death ligand 1) has led to advances in the treatment of melanoma and non-small cell lung cancer
(NSCLC). The use of such therapies has also been introduced into the treatment of other malignancies, including
head and neck cancer. The combined effects of checkpoint inhibitors and anti-PD1(L1) antibodies and radiation
therapy have not yet been sufficiently investigated.
Case presentation: We report a case of locally relapsed non-resectable oral cavity squamous cell carcinoma, with
excellent local control after pembrolizumab (MK3475) followed by radiotherapy.
Conclusion: T cell activation induced by checkpoint inhibition may dramatically improve tumor response to
radiation. More data are needed to identify the toxicity and efficacy of sequential or concurrent checkpoint
inhibitors and radiotherapy.
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Background
The development of immunotherapy targeting the
PD1/PDL1 checkpoint inhibition pathway represents
considerable progress in the treatment of many cancer
types. Pembrolizumab is a humanized monoclonal
antibody that blocks the interaction of PD-1 with its
ligands, PD-L1 and PD-L2. It is FDA approved for the
treatment of melanoma and NSCLC and was recently
granted accelerated approval for the treatment of re-
current or metastatic head and neck squamous cell
carcinoma in patients with disease progression on or
after platinum-containing chemotherapy [1]. Little is
known regarding the effects of radiation following
PD1 inhibition. We report a case of a patient who ex-
perienced excellent local control with immunotherapy
followed by radiation therapy for relapsed oral cavity
cancer.
Case presentation
A 66 year old woman with floor of mouth squamous
cell carcinoma (SCC) presented to our institution after
her second relapse. Originally diagnosed in 2006, she
had undergone a composite resection with a flap re-
construction and bilateral neck dissections followed by
post-surgical adjuvant radiotherapy for stage IVa
(T4aN0M0) disease. Immunohistochemistry (IHC)
staining for p16 was negative. In May of 2009, a re-
sectable locoregional recurrence was detected and
consequently treated with a composite resection utiliz-
ing a pectoralis flap reconstruction. In November of
2013, she presented with a second non-resectable
locoregional relapse. She received carboplatin and pac-
litaxel for 4 cycles with a partial response (PR) after
2 cycles. The patient subsequently developed regional
progression and was treated with weekly methotrexate
and cetuximab and she achieved stable disease (SD)
for 6 months. Later, she progressed locally and was
enrolled into a trial utilizing single agent pembrolizu-
mab. She had SD for 6 cycles (Fig. 1), and then
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suffered from local progression with a significant in-
crease in the size of her neck mass, with painful ulcer-
ation and bleeding. Pembrolizumab was therefore
discontinued. At this time restaging studies revealed
no evidence of distant metastasis. She required mul-
tiple transfusions secondary to tumor hemorrhage and
as a result was treated palliatively with radiation ther-
apy to a total dose of 30 Gy directed at the mass. The
patient experienced an excellent clinical response.
Bleeding had resolved (Fig. 2) and her pain had greatly
improved. A significant radiographic response was
also noted on computed tomography (CT) scan, with
tumor dimensions decreasing by 60 %, from 7.1 ×
7.2 cm pre-radiation, to 5.9 × 3.4 cm, 6 weeks post-
radiation.
Discussion
Pembrolizumab in head and neck cancer
The strongest available data for checkpoint inhibitors
in head and neck SCC are from an expansion cohort of
a phase Ib study (KEYNOTE-012), utilizing pembroli-
zumab in the recurrent/metastatic setting (Table 1).
One hundred and ninety-two patients were enrolled.
Confirmed objective response rate (ORR) was 17.7 %
(95 % CI, 12.6–23.9 %; 7 complete responses [CRs], 27
PRs). Thirty three (17 %) patients achieved stable dis-
ease. ORR was seen in 21.9 % (95 % CI, 12.5–34.0 %) of
HPV (human papilloma virus) positive and in 15.9 %
(95 % CI, 10.0–23.4 %) of HPV negative patients. The
median overall survival (OS) was 8.5 months (95 % CI,
6.5–10.5). These were patients who were heavily pre-
treated and a majority of them had more than two lines
of previous therapy. Treatment-related adverse events
(TRAEs) occurred in 122 (64 %) patients; 23 (12 %) pa-
tients had a grade 3–4 TRAE [2].
Radiation therapy and immunotherapy
The effects of radiation following PD1 inhibition are
unknown. Current data come from the concurrent ad-
ministration of immune checkpoint inhibitors with
radiotherapy. Radiation is thought to enhance antitu-
mor immune responses by causing inflammatory cell
death, major histocompatibility complex (MHC) I up-
regulation, and release of antigens that are taken up by
dendritic cells [3]. Mouse models have shown increased
PD-L1 expression in tumors following irradiation [4].
The abscopal effect; or the phenomenon in which
tumor regression occurs at sites distant from the site of
radiation, has been documented in melanoma and
NSCLC patients who underwent radiation with ipilimu-
mab, a CTLA-4 (cytotoxic T-lymphocyte-associated
protein 4) checkpoint inhibitors [5, 6]. This further
supports the concept of synergistic activity between
checkpoint inhibitors and radiation.
Identifying the most beneficial timing for combined
radiotherapy and immunotherapy remains a challenge.
If radiation is given prior to, or concurrently with im-
munotherapy, immunotherapy may be more effective
with tumor specific antigens originally generated by
radiotherapy. On the other hand, if immunotherapy is
Fig. 1 Change in largest dimensions of neck mass on CT scans over treatment period. a Prior to pembrolizumab. 8.8 × 5.9 cm. b Best response to
pembrolizumab. 6 × 4 cm. c Progression on pembrolizumab. 7.1 × 7.2 cm. d Post radiation 5.9 × 3.4 cm
Fig. 2 Appearance of neck mass post pembrolizumab and radiation therapy. a Local control was achieved after 6 cycles of single agent pembrolizumab
therapy. b The bleeding mass resolved after radiation therapy
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delivered before radiotherapy, the active immune
microenvironment may maximize radiation efficacy [7].
In the present case, radiotherapy was given immediately
following discontinuation of pembrolizumab in an at-
tempt to control bleeding. The excellent response seen
in the present case may be attributed from the synergis-
tic effect of pembrolizumab.
One possible disadvantage of the concurrent adminis-
tration of checkpoint inhibitors and radiation is the po-
tential for added toxicities. In the present case, it is
probable that the risk of adverse events (AE) was miti-
gated by the sequential delivery of therapy. In an ana-
lysis of 29 unresectable/metastatic melanoma patients
who underwent radiation while receiving ipilimumab,
the authors concluded that concurrent therapy was not
associated with higher than expected rates of AEs, nor
did it invalidate the palliative effects of radiation or sur-
vival benefits from ipilimumab [8, 9].
Several clinical trials are evaluating combined radiother-
apy and checkpoint inhibitors in head and neck SCC
(Table 2). The phase Ib study of cetuximab, ipilimumab
and intensity modulated radiation therapy (IMRT) in stage
III-IVa HPV+ oropharyngeal SCC (NCT01935921) and
the phase II study of concurrent versus sequential pem-
brolizumab, cisplatin and IMRT in stage III-IVb head and
neck SCC are currently accruing patients (NCT0277385).
Conclusion
As we await further data, a trial of radiation following
immunotherapy could be considered for disease control
in selected patients.
Table 1 Ongoing trials on PD1 inhibitors in HNSCC
Abbreviated Trial
Name/NCT#








Ib Pembrolizumab Recurrent/metastatic HNSCC ORR 17.7 % (95 % CI,
12.6–23.9 %; 7 CRs, 27 PRs).
HPV+ 21.9 %, HPV- 15.9 %.
Median OS 8.5 mo (95 % CI,
6.5–10.5).
Grade 3–4; 12 %





II Pembrolizumab Recurrent/metastatic HNSCC,
progressed on platinum and
cetuximab
ORR 18 % (95%CI 9–31);
HPV+ 22 %, HPV- 16 %
SD 18 %













III Pembrolizumab VS P
embro + cis/carbo + 5FU
VS Cetuximab + cis/carbo
+ 5FU







III Nivolumab VS Chemo
(methotrexate, docetaxel
or cetuximab)
Recurrent/metastatic HNSCC 1 year OS; nivo 36 %, chemo
16.6 %
Median OS; nivo 7.5 mon,
chemo 5.1 months
Table 2 Ongoing studies on PD1 inhibitors and radiation therapy in HNSCC
Abbreviated Trial Name/
NCT#
Phase Agent(s) Study population Expected Primary Endpoint
NCT01935921 Ib Cetuximab, ipilimumab and IMRT stage III-IVa
HPV+ OPSCC





Nivolumab and cisplatin CRT stage III-IV, intermediate to high risk
HNSCC
DLT for phase I









I Adjuvant pembro, cisplatin and
IMRT
high risk stage III-IV HSNCC DLT
NCT02641093 II Adjuvant pembro, cisplatin and
IMRT
high risk stage III-IV HSNCC Treatment related adverse events
(TRAE)
Disease free survival (DFS)
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